3.8

CiteScore

2.4

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Xuezhong Wang, Xiaoxuan Gong, Tiantian Zhu, Qiu Zhang, Yangyang Zhang, Xiaowei Wang, Zhijian Yang, Chunjian Li. Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery[J]. The Journal of Biomedical Research, 2014, 28(2): 108-113. DOI: 10.7555/JBR.28.20120139
Citation: Xuezhong Wang, Xiaoxuan Gong, Tiantian Zhu, Qiu Zhang, Yangyang Zhang, Xiaowei Wang, Zhijian Yang, Chunjian Li. Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery[J]. The Journal of Biomedical Research, 2014, 28(2): 108-113. DOI: 10.7555/JBR.28.20120139

Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery

Funds: 

This work was supported by a grant from the National Natural Science Foundation of China (81170181), and a Program for Development of Innovative Research Team in the First Affiliated Hospital of Nanjing Medical University, and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutes (PAPD).

More Information
  • Received Date: December 13, 2012
  • We sought to assess the incidence of aspirin resistance after off-pump coronary artery bypass (OPCAB) surgery, and investigate whether clopidogrel can improve aspirin response and be safely applied early after OPCAB surgery. Sixty patients who underwent standard OPCAB surgery were randomized into two groups. One group (30 patients) received mono-antiplatelet treatment (MAPT) with aspirin 100 mg daily and the other group received dual antiplatelet treatment (DAPT) with aspirin 100 mg daily plus clopidogrel 75 mg daily. Platelet aggregations in response to arachidonic acid (PLAA) and adenosine diphosphate (ADP) (PLADP) were measured preoperatively and on days 1 to 6, 8 and 10 after the antiplatelet agents were administered. A PLAA level above 20% was defined as aspirin resistance. Postoperative bleeding and other perioperative variables were also recorded. There were no significant differences between the two groups in baseline characteristics, average number of distal anastomosis, operation time, postoperative bleeding, ventilation time and postoperative hospital stay. However, the incidence of aspirin resistance was significantly lower in the DAPT group than that in the MAPT group on the first and second day after antiplatelet agents were given (62.1% vs. 32.1%, 34.5% vs. 10.7%, respectively, both P , 0.05). There was no significant difference in postoperative complication between the two groups. DAPT with aspirin and clopidogrel can be safely applied to OPCAB patients early after the procedure. Moreover, clopidogrel reduces the incidence of OPCAB-related aspirin resistance.
  • Related Articles

    [1]Wenqu Li, Zhenlong Wang, Huizhi Qi, Chengjie Xia, Feixue Chen, Juan Xu, Lei Zhang, Xuemei Jia. The association between HPV infection and endometriosis: Risk and fertility outcomes[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.39.20250194
    [2]Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
    [3]Tao Chun'ai, Gan Yongxin, Su Weidong, Li Zhutian, Tang Xiaolan. Effectiveness of hospital disinfection and experience learnt from 11 years of surveillance[J]. The Journal of Biomedical Research, 2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
    [4]Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
    [5]Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
    [6]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [7]Fengzhen Wang, Mingwan Zhang, Dongsheng Zhang, Yuan Huang, Li Chen, Sunmin Jiang, Kun Shi, Rui Li. Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery[J]. The Journal of Biomedical Research, 2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
    [8]Christopher J. Danford, Zemin Yao, Z. Gordon Jiang. Non-alcoholic fatty liver disease: a narrative review of genetics[J]. The Journal of Biomedical Research, 2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045
    [9]Hong-mei Gu, Da-wei Zhang. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9[J]. The Journal of Biomedical Research, 2015, 29(5): 356-361. DOI: 10.7555/JBR.29.20150067
    [10]Joseph M. Miano. Myocardin in biology and disease[J]. The Journal of Biomedical Research, 2015, 29(1): 3-19. DOI: 10.7555/JBR. 29.20140151
  • Cited by

    Periodical cited type(15)

    1. Arsh H, Manoj Kumar F, Simran F, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Ann Med Surg (Lond), 2024, 86(2): 899-908. DOI:10.1097/MS9.0000000000001601
    2. Saputri FC, Azmi NU, Puteri MU, et al. High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study. Nutrients, 2023, 15(20): 4463. DOI:10.3390/nu15204463
    3. Ishikawa H, Nagashima R, Kuno Y, et al. Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice. Diabetes Metab Syndr Obes, 2023, 16: 2855-2864. DOI:10.2147/DMSO.S428190
    4. Chen PW, Tseng SY, Chang HY, et al. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. Int J Mol Sci, 2022, 23(17): 9768. DOI:10.3390/ijms23179768
    5. Ayoub C, Azar Y, Maddah D, et al. Low circulating PCSK9 levels in LPL homozygous children with chylomicronemia syndrome in a syrian refugee family in Lebanon. Front Genet, 2022, 13: 961028. DOI:10.3389/fgene.2022.961028
    6. Bouchard J, Malalgoda M, Storsley J, et al. Health Benefits of Cereal Grain- and Pulse-Derived Proteins. Molecules, 2022, 27(12): 3746. DOI:10.3390/molecules27123746
    7. Majeed ML, Ghafil FA, Fatima G, et al. Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J Clin Biochem, 2021, 36(1): 74-80. DOI:10.1007/s12291-019-00858-5
    8. Fedoryak O, Arama C, Diarra I, et al. Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children. Can J Infect Dis Med Microbiol, 2020, 2020: 9340480. DOI:10.1155/2020/9340480
    9. Drouin-Chartier JP, Tremblay AJ, Hogue JC, et al. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. J Lipid Res, 2018, 59(8): 1501-1509. DOI:10.1194/jlr.M086264
    10. Chan DC, Watts GF, Somaratne R, et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol, 2018, 38(7): 1644-1655. DOI:10.1161/ATVBAHA.118.310882
    11. Eroğlu Z, Tetik Vardarlı A, Düzgün Z, et al. Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. Anatol J Cardiol, 2018, 19(5): 334-340. DOI:10.14744/AnatolJCardiol.2018.86648
    12. Hedayat AF, Park KH, Kwon TG, et al. Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model. Transl Res, 2018, 192: 30-45. DOI:10.1016/j.trsl.2017.10.007
    13. Chen IC, Tseng WK, Li YH, et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget, 2017, 8(64): 108042-108053. DOI:10.18632/oncotarget.22448
    14. Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Exp Ther Med, 2017, 13(3): 810-814. DOI:10.3892/etm.2017.4055
    15. Yu Z, Huang T, Zheng Y, et al. PCSK9 variant, long-chain n-3 PUFAs, and risk of nonfatal myocardial infarction in Costa Rican Hispanics. Am J Clin Nutr, 2017, 105(5): 1198-1203. DOI:10.3945/ajcn.116.148106

    Other cited types(0)

Catalog

    Chunjian Li

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    Article Metrics

    Article views (3877) PDF downloads (804) Cited by(15)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return